- Turkish Journal of Internal Medicine
- Vol: 3 Issue: Supplement 1 Special Issue
- Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplast...
Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
Authors : Ibrahim Ethem Pinar, Fahir Özkalemkaş, Vildan Ozkocaman, Tuba Ersal, Cumali Yalçin, Bedrettin Orhan, Ömer Candar
Pages : 42-43
Doi:10.46310/tjim.877068
View : 21 | Download : 5
Publication Date : 2021-03-07
Article Type : Other
Abstract :The management of acute myeloid leukemia (AML) gradually turns into an individualized approach with the application of targeted therapies. Venetoclax is a BCL-2 inhibitor that is synergistic with azacitidine. In this case series, 14 patients diagnosed with relapsed / refractory AML and 1 MDS RAEB-1 were followed up with venetoclax + azacitidine in the Hematology Department Bursa Uludag University Faculty of Medicine were evaluated. The best responses obtained with venetoclax + azacitidine were complete remission (CR) in one patient, complete remission with incomplete hematologic recovery (CRi) in one patient, morphological leukemia-free state (MLFS) in 4 patients, and partial response (PR) in one patient. The median time to first response with treatment was one month (0.5-5). The time to enter early remission is critical. For this reason, deaths due to infection should be prevented. Although the toxicities of this combination therapy can be managed, close follow-up of the patients is mandatory. In conclusion, this combination therapy is promising as it is relatively well-tolerated, improves the quality of life, and prolongs survival.Keywords : Venetoclax, azacitidine, acute myeloid leukemia, myelodysplastic syndrome